TB-500 is marketed as a thymosin-beta-4-related recovery peptide. The sources currently linked to this profile are regulatory records, not human efficacy studies. It is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026.
Research peptide
TB-500
TB-500 is marketed as a thymosin-beta-4-related recovery peptide. The sources currently linked to this profile are regulatory records, not human efficacy studies. It is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026.
Regulatory watch
Last reviewed Jul 12, 2026
Next review Jul 24, 2026
Evidence snapshot
Human evidence: no efficacy study is included in the current reviewed source set.
Claim pattern: online marketing commonly associates TB-500 with injury recovery and tissue repair.
Regulatory status: TB-500 is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026.
Research record
What the evidence record says
- Evidence grade
- Not Graded
- Regulatory status
- TB-500 regulatory status has not been fully reviewed by Peptide Report editorial team. See company profiles and regulatory watch for current status.
Evidence records
Studies, registries, reviews, and regulatory records
Evidence review pending
- Detailed evidence review for TB-500 is pending editorial assessment. Current summary reflects available public records.
Records: FDA compounding advisory committee July 2026: peptides, FDA BPC-157 compounding safety risk: immunogenicity
Evidence timeline
What changed, and when
Peptide Report last reviewed TB-500 on 2026-07-12.
Records: FDA compounding advisory committee July 2026: peptides
Direct answers
Frequently asked questions
What is TB-500?
TB-500 is a research peptide tracked by Peptide Report. See the full profile for current editorial assessment.
Open research questions
What is still unknown
- What is the complete human evidence base for TB-500?
- What are the long-term safety considerations for TB-500?
Tracked claims
TB-500 is commonly grouped with recovery-oriented peptide discussions.
Evidence level: Public discussion / regulatory watch
Sources: FDA compounding advisory committee July 2026: peptides
How to read this: The current sources document a public claim pattern and regulatory review, not a demonstrated recovery benefit.
TB-500 was scheduled for FDA advisory committee review in July 2026.
Evidence level: Primary regulatory
Sources: FDA compounding advisory committee July 2026: peptides
How to read this: An advisory committee proceeding does not establish approval, safety, or efficacy.
Linked public records
Regulatory actions involving TB-500
FDA advisory committee to review seven peptide-related bulk drug substances
Scheduled · Scheduled public meeting
FDA scheduled a two-day Pharmacy Compounding Advisory Committee meeting to discuss whether BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax, and Epitalon-related substances should be included on the 503A Bulks List. The committee provides advice; the meeting itself is not a final agency determination.
Compounds: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate TB-500 claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Formspree processes this submission for Peptide Report. Privacy notice.
Sources on this page
Each source record is linked to the claim or evidence note it supports.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA Pharmacy Compounding Advisory Committee meeting notice for July 23 to 24, 2026, scheduling peptide bulk substances for discussion.
23 linked pagesOpen original ·
fda-pcac-july-2026Certain bulk drug substances for use in compounding may present significant safety risks
FDA risk page lists BPC-157: compounded BPC-157 may pose immunogenicity risk and peptide-related impurity concerns for certain routes of administration.
41 linked pagesOpen original ·
fda-bulk-risk-listRelated compounds
BPC-157
BPC-157 is an experimental peptide with extensive animal research but very limited human evidence. A Phase 1 registry re...
Regulatory watchDSIP
Delta sleep-inducing peptide, or DSIP, was studied in small human sleep experiments during the 1970s and 1980s. Results ...
Regulatory watchEpitalon
Epitalon is a synthetic tetrapeptide promoted for longevity and telomere-related effects. The reviewed evidence rests la...
Regulatory watchKPV
KPV is a three-amino-acid fragment derived from alpha-melanocyte-stimulating hormone. Anti-inflammatory findings come fr...
Regulatory watchStay informed
Track TB-500 with Peptide Report
Get FDA Watch Alerts for TB-500
Subscribe for regulatory updates, new trial data, and source-backed claim revisions.
Compare TB-500 with similar compounds
1 comparison page available:
BPC-157 vs TB-500